Adjuvant Transarterial Chemoembolization Plus Immunotherapy for Huge Hepatocellular Carcinoma: A Propensity Score Matching Cohort Study

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Elhanafy E, Aboelinin M, Said R, et al. Outcomes of liver resection for huge hepatocellular carcinoma exceeding 10 cm in size: a single center experience. Am J Surg. 2023;225(6):1013–1021. doi:10.1016/j.amjsurg.2022.12.005
   PubMed Web of Science ®Google Scholar
• Wang J-C, Hou J-Y, Chen J-C, et al. Development and validation of prognostic nomograms for single large and huge hepatocellular carcinoma after curative resection. Eur J Cancer. 2021;155:85–96. doi:10.1016/j.ejca.2021.07.009
   PubMed Web of Science ®Google Scholar
• Wei C-Y, Chen P-C, Chau G-Y, et al. Comparison of prognosis between surgical resection and transarterial chemoembolization for patients with solitary huge hepatocellular carcinoma. Ann Transl Med. 2020;8(5):238. doi:10.21037/atm.2019.12.157
   PubMed Web of Science ®Google Scholar
• Bogdanovic A, Bulajic P, Masulovic D, Bidzic N, Zivanovic M, Galun D. Liver resection versus transarterial chemoembolization for huge hepatocellular carcinoma: a propensity score matched analysis. Sci Rep. 2021;11(1):4493.
   PubMed Web of Science ®Google Scholar
• Fang Q, Xie Q-S, Chen J-M, et al. Long-term outcomes after hepatectomy of huge hepatocellular carcinoma: a single-center experience in China. Hepatobiliary Pancreat Dis Int. 2019;18(6):532–537. doi:10.1016/j.hbpd.2019.09.001
   PubMed Web of Science ®Google Scholar
• Wang L, Liu Z, Liu X, Zeng Y, Liu J. The hepatectomy efficacy of huge hepatocellular carcinoma and its risk factors: a meta analysis. Medicine. 2017;96(52):e9226. doi:10.1097/MD.0000000000009226
   PubMed Web of Science ®Google Scholar
• Wang Z, Ren Z, Chen Y, et al. Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study. Clin Cancer Res. 2018;24(9):2074–2081. doi:10.1158/1078-0432.CCR-17-2899
   PubMed Web of Science ®Google Scholar
• Li S, Mei J, Wang Q, et al. Postoperative adjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of hepatocellular carcinoma patients with microvascular invasion: a preliminary report of a Phase III, randomized controlled clinical trial. Ann Surg Oncol. 2020;27(13):5183–5190. doi:10.1245/s10434-020-08601-8
   PubMed Web of Science ®Google Scholar
• Wang W-H, Wang Z, J-X W, et al. Survival benefit with IMRT following narrow-margin hepatectomy in patients with hepatocellular carcinoma close to major vessels. Liver Int. 2015;35(12):2603–2610. doi:10.1111/liv.12857
   PubMed Web of Science ®Google Scholar
• Zhang X-P, Chai Z-T, Gao Y-Z, et al. Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis. HPB. 2019;21(12):1687–1696. doi:10.1016/j.hpb.2019.04.014
   PubMed Web of Science ®Google Scholar
• Chen W, Hu S, Liu Z, et al. Adjuvant anti-PD-1 antibody for hepatocellular carcinoma with high recurrence risks after hepatectomy. Hepatol Int. 2023;17(2):406–416. doi:10.1007/s12072-022-10478-6
   PubMed Web of Science ®Google Scholar
• Wei W, Jian P-E, S-h L, et al. Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety. Cancer Commun. 2018;38(1):61. doi:10.1186/s40880-018-0331-y
   PubMed Web of Science ®Google Scholar
• Chen W, Ma T, Zhang J, et al. A systematic review and meta-analysis of adjuvant transarterial chemoembolization after curative resection for patients with hepatocellular carcinoma. HPB. 2020;22(6):795–808. doi:10.1016/j.hpb.2019.12.013
   PubMed Web of Science ®Google Scholar
• Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6):1922–1965. doi:10.1097/HEP.0000000000000466
   PubMed Web of Science ®Google Scholar
• Qin S, Chen M, Cheng A-L, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, Phase 3 trial. Lancet. 2023;402(10415):1835–1847. doi:10.1016/S0140-6736(23)01796-8
   PubMed Web of Science ®Google Scholar
• Kubota K, Makuuchi M, Kusaka K, et al. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology. 1997;26(5):1176–1181. doi:10.1053/jhep.1997.v26.pm0009362359
   PubMed Web of Science ®Google Scholar
• Zhang B, Xu D, Wang R, et al. Perioperative antiviral therapy improves safety in patients with hepatitis B related HCC following hepatectomy. Int J Surg. 2015;15:1–5. doi:10.1016/j.ijsu.2014.12.030
   PubMed Web of Science ®Google Scholar
• Chen XP, Qiu FZ, Wu ZD, Zhang BX. Chinese experience with hepatectomy for huge hepatocellular carcinoma. Br J Surg. 2004;91(3):322–326. doi:10.1002/bjs.4413
   PubMed Web of Science ®Google Scholar
• Xu X, Zhang H-L, Liu Q-P, et al. Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma. J Hepatol. 2019;70(6):1133–1144. doi:10.1016/j.jhep.2019.02.023
   PubMed Web of Science ®Google Scholar
• Cong W-M, Bu H, Chen J, et al. Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol. 2016;22(42):9279–9287. doi:10.3748/wjg.v22.i42.9279
   PubMed Web of Science ®Google Scholar
• Min YW, Lee JH, Gwak G-Y, et al. Long-term survival after surgical resection for huge hepatocellular carcinoma: comparison with transarterial chemoembolization after propensity score matching. J Gastroenterol Hepatol. 2014;29(5):1043–1048. doi:10.1111/jgh.12504
   PubMed Web of Science ®Google Scholar
• Wang H, Yu H, Qian Y-W, Cao Z-Y, Wu M-C, Cong W-M. Postoperative adjuvant transcatheter arterial chemoembolization improves the prognosis of patients with huge hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2021;20(3):232–239. doi:10.1016/j.hbpd.2020.12.018
   PubMed Web of Science ®Google Scholar
• Li J, Wang W-Q, Zhu R-H, et al. Postoperative adjuvant tyrosine kinase inhibitors combined with anti-PD-1 antibodies improves surgical outcomes for hepatocellular carcinoma with high-risk recurrent factors. Front Immunol. 2023;14:1202039. doi:10.3389/fimmu.2023.1202039
   PubMed Web of Science ®Google Scholar
• Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25(1):267–296. doi:10.1146/annurev.immunol.25.022106.141609
   PubMed Web of Science ®Google Scholar
• Zhu X-D, K-s L, Sun H-C. Adjuvant therapies after curative treatments for hepatocellular carcinoma: current status and prospects. Genes Dis. 2020;7(3):359–369. doi:10.1016/j.gendis.2020.02.002
   PubMed Web of Science ®Google Scholar
• Jiang N, Zhong B, Huang J, et al. Transarterial chemoembolization combined with molecularly targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a retrospective cohort study. Front Immunol. 2023;14:1205636. doi:10.3389/fimmu.2023.1205636
   PubMed Web of Science ®Google Scholar
• Zhang J-X, Chen P, Liu S, Q-q Z, Shi H-B, Zhou C-G. Safety and efficacy of transarterial chemoembolization and immune checkpoint inhibition with camrelizumab for treatment of unresectable hepatocellular carcinoma. J Hepatocell Carcinoma. 2022;9:265–272. doi:10.2147/JHC.S358658
   PubMed Web of Science ®Google Scholar
• Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(8):525–543.
   PubMed Web of Science ®Google Scholar
• J-c W, Huang Y-H, Chau G-Y, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol. 2009;51(5):890–897. doi:10.1016/j.jhep.2009.07.009
   PubMed Web of Science ®Google Scholar
• Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38(2):200–207. doi:10.1016/S0168-8278(02)00360-4
   PubMed Web of Science ®Google Scholar
• Wakayama K, Kamiyama T, Yokoo H, et al. Huge hepatocellular carcinoma greater than 10 cm in diameter worsens prognosis by causing distant recurrence after curative resection. J Surg Oncol. 2017;115(3):324–329.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label Phase 2 trial. Lancet Oncol. 2018;19(7):940–952. doi:10.1016/S1470-2045(18)30351-6
   PubMed Web of Science ®Google Scholar
• Ren Z, Ducreux M, Abou-Alfa GK, et al. Tislelizumab in patients with previously treated advanced hepatocellular carcinoma (RATIONALE-208): a multicenter, non-randomized, open-label, Phase 2 trial. Liver Cancer. 2023;12(1):72–84. doi:10.1159/000527175
   PubMed Web of Science ®Google Scholar
• Hwang S, Lee Y-J, Kim K-H, et al. Long-term outcome after resection of huge hepatocellular carcinoma ≥ 10 cm: single-institution experience with 471 patients. World J Surg. 2015;39(10):2519–2528. doi:10.1007/s00268-015-3129-y
   PubMed Web of Science ®Google Scholar
• Ercolani G, Grazi GL, Ravaioli M, et al. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg. 2003;237(4):536–543. doi:10.1097/01.SLA.0000059988.22416.F2
   PubMed Web of Science ®Google Scholar
• Harada N, Shirabe K, Maeda T, Kayashima H, Ishida T, Maehara Y. Blood transfusion is associated with recurrence of hepatocellular carcinoma after hepatectomy in Child-Pugh class A patients. World J Surg. 2015;39(4):1044–1051. doi:10.1007/s00268-014-2891-6
   PubMed Web of Science ®Google Scholar